Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Antimicrobial Agents and Chemotherapy
Miguel Angel Martinez

Abstract

Currently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb a...Continue Reading

References

Jul 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·E DuarteJ Holland
Apr 12, 2003·The New England Journal of Medicine·Christian DrostenHans Wilhelm Doerr
Aug 31, 2006·Annals of Internal Medicine·Thomas C LukeStephen L Hoffman
Oct 19, 2012·The New England Journal of Medicine·Ali M ZakiRon A M Fouchier
May 3, 2013·Nature·Kari Ann ShireyStefanie N Vogel
Oct 8, 2013·The Journal of Infection·Jasper F W ChanKwok-Yung Yuen
Feb 11, 2015·Antiviral Research·Yanchen ZhouGraham Simmons
Mar 8, 2016·The Cochrane Database of Systematic Reviews·Chamira RodrigoWei Shen Lim
Nov 29, 2016·Nature Microbiology·Adam S CockrellRalph S Baric
Jul 1, 2017·Science Translational Medicine·Timothy P SheahanRalph S Baric
Nov 22, 2017·American Journal of Respiratory and Critical Care Medicine·Yaseen M ArabiUNKNOWN Saudi Critical Care Trial Group
Nov 28, 2019·The New England Journal of Medicine·Sabue MulanguUNKNOWN PALM Consortium Study Team
Jan 25, 2020·The New England Journal of Medicine·Na ZhuUNKNOWN China Novel Coronavirus Investigating and Research Team
Jan 28, 2020·Lancet·Chen WangGeorge F Gao
Feb 6, 2020·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin· Eurosurveillance Editorial Team
Feb 15, 2020·Proceedings of the National Academy of Sciences of the United States of America·Emmie de WitHeinz Feldmann
Feb 18, 2020·Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·UNKNOWN Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention

❮ Previous
Next ❯

Citations

Apr 6, 2020·Clinical and Experimental Pharmacology & Physiology·Siliang ZhuFanpo Kong
Apr 3, 2020·Journal of Medical Virology·Qing YeTing Zhang
Apr 4, 2020·Pediatric Research·Eleanor J Molloy, Cynthia F Bearer
Apr 25, 2020·British Journal of Haematology·Noémi Ba RoyUNKNOWN National Haemoglobinopathy Panel
Apr 18, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Mario Fernández-RuizJosé M Aguado
May 13, 2020·Journal of Cellular Physiology·Bahman YousefiMajid Eslami
Apr 28, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Yaerim KimSeungyeup Han
May 23, 2020·Journal of Clinical Pharmacology·Luca GallelliFenghua Fu
Apr 15, 2020·Neurology·Amanda C Guidon, Anthony A Amato
May 6, 2020·British Journal of Pharmacology·Hong ZhouXiao-Ming Meng
Jun 6, 2020·JAMA Pediatrics·Anil R MaharajUNKNOWN Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
May 10, 2020·International Journal of Clinical Pharmacy·Alessio Provenzani, Piera Polidori
Jun 9, 2020·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Alessandro FavilliSandro Gerli
Apr 16, 2020·Journal of Medical Virology·Silvia MascoloVincenzo Esposito
Jul 16, 2020·Pathogens and Disease·Zhilong JiaKunlun He
May 20, 2020·Antimicrobial Agents and Chemotherapy·James T GordyNoton K Dutta
Jul 9, 2020·Canadian Journal of Physiology and Pharmacology·Ellen WeisbergJames D Griffin
Jul 1, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith SigelBenjamin S Glicksberg
Jul 22, 2020·British Journal of Clinical Pharmacology·Michael G DoddsCraig R Rayner
Jul 15, 2020·Nature Nanotechnology·Helena F FlorindoRonit Satchi-Fainaro
Jun 1, 2020·The International Journal of Risk & Safety in Medicine·Lo'ai AlanagrehManar Atoum
Jul 8, 2020·Antimicrobial Agents and Chemotherapy·Miguel Angel Martinez
Mar 29, 2020·Journal of Medical Virology·Beuy Joob, Viroj Wiwanitkit
Aug 9, 2020·Cell Biology International·Mahmood S Choudhery, David T Harris
Sep 5, 2020·Immunopharmacology and Immunotoxicology·Arzu Didem Yalcin, Ata Nevzat Yalcin
Sep 6, 2020·Pharmacological Reports : PR·Thakur Uttam SinghRaj Kumar Singh
Apr 4, 2020·The Journal of Nutrition, Health & Aging·J E Morley, B Vellas
Apr 25, 2020·International Journal of Molecular Sciences·Ayumu AsaiHideshi Ishii
Jul 16, 2020·International Journal of Molecular Sciences·Jiří Czernek, Jiří Brus
Jul 15, 2020·Open Forum Infectious Diseases·Joshua T SchifferLawrence Corey
Jun 10, 2020·Bulletin of the National Research Centre·Manal A Hamed
Aug 18, 2020·Expert Opinion on Emerging Drugs·Sujit DebnathAbdelwahab Omri
Sep 4, 2020·Molecular Diversity·Probir Kumar OjhaJerzy Leszczynski
May 26, 2020·Expert Opinion on Emerging Drugs·Yanyi TaoYu Hu
Apr 1, 2020·Drug Development Research·Leonardo CaputoSolomon Habtemariam
Aug 21, 2020·Pharmacological Reports : PR·Adeleh SahebnasaghAmirhosein Khoshi
Jun 4, 2020·Molecular Cancer·Wei FengShaoqing Ju
Jul 23, 2020·MSystems·Daniel van der Lelie, Safiyh Taghavi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transgenic

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Liver International : Official Journal of the International Association for the Study of the Liver
Ling XuXin Zheng
Proceedings of the National Academy of Sciences of the United States of America
Emmie de WitHeinz Feldmann
© 2021 Meta ULC. All rights reserved